SOURCE: Advatech Corporation

June 17, 2008 15:35 ET

Advatech Corp. Announces Research Study at the Kennedy Krieger Institute

WEST PALM BEACH, FL--(Marketwire - June 17, 2008) - Advatech Corporation (PINKSHEETS: ADVA) today announced that it has entered into an Agreement with the Kennedy Krieger Institute of Johns Hopkins University. Pursuant to the Agreement, the Kennedy Krieger Institute has commenced research utilizing Advatech's patented Field Therapy Accelerator ("FTA") device and related technologies. Initial trials will focus on "in-vitro" studies of the enhancement of stem cell cultures as well as the potential development of treatment for spinal cord injuries. Future "in-vivo" studies of stem cell implantation are also intended. The Kennedy Krieger Institute, located in Baltimore, MD, is an internationally recognized research institute renowned for its work in pioneering new interventions and diagnosis and understanding disorders and injuries of the brain and spinal cord.

In a previous release dated November 14, 2007, Advatech announced that the U.S. Patent Office delivered to Advatech an Issued Patent covering the Company's FTA device and related technologies. The patent (No.7,288,062) delineates with both Apparatus and Method Claims the unique design and process which involves therapeutic charge transfer in tissue. Advatech's FTA is intended to provide the non-invasive treatment of many forms of trauma using an electric field.

Dr. Michael Spiegel, Advatech's Chief Science Officer and Director of Research, stated, "We are excited by the multiple potential commercial applications of our technology as no other non-invasive electrical therapy offers the sustained level of energy transfer provided by the FTA. Our continued efforts to demonstrate the effectiveness of our FTA offer the Company the ability to move closer toward successful commercialization and an attractive financial opportunity for the Company."

About Advatech Corp.

Advatech Corporation is an early stage biotechnology company engaged in the research and development and the commercialization of non-invasive electrical therapies. To date, various tests of Advatech's FTA have demonstrated promising results in areas as varied as rapid wound and burn healing, genetic regulation, and stimulation of cell growth. The promise shown by positive in-vitro and pre-clinical results further indicate a wide variety of future applications. Advatech's breakthrough solution allows powerful non-invasive electrical therapy that has the potential to positively impact healthcare delivery. The Company continues to investigate a variety of applications for its unique patented Intellectual Property and technology.

Our Commercialization Plans

Advatech's commercialization strategy is focused on establishing either partnerships or commercial licensing agreements with motivated licensees. These targeted potential licensees or strategic partnerships will offer the necessary development, manufacturing, sales, marketing resources, and capital required to bring Advatech's technology to market.

Shareholder Value

Advatech's Management believes that the current share price does not accurately reflect the true value of what the Company has been able to accomplish to date. The results of Management's efforts have not yet translated into share value nor the generation of revenues. Historically, ADVA shares have traded on the OTC market. In order for the shares to be quoted and traded on the Pink Sheets, NASD rules require that a broker/dealer submit information to the NASD gathered pursuant to the Securities and Exchange Act of 1934 (Exchange Act) Rule 15c2-11 before initiating a quotation in the Pink Sheets. The Company intends, as soon as practicable, to begin the process to have its shares quoted and traded on the Pink Sheets. Once trading on Pink Sheets, the Company believes that its common stock may be more likely to attract additional shareholders and investors with a resulting increase in trading transparency and liquidity while developing a broad base "ownership culture."

Safe Harbor Statement

This release includes forward-looking Statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information